Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release

David B. Horton, Kiran B. Siripurapu, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics October 2011, 339 (1) 286-297; DOI: https://doi.org/10.1124/jpet.111.184770
David B. Horton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiran B. Siripurapu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangrong Zheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Crooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda P. Dwoskin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Lobelane, a chemically defunctionalized saturated analog of lobeline, has increased selectivity for the vesicular monoamine transporter 2 (VMAT2) compared with the parent compound. Lobelane inhibits methamphetamine-evoked dopamine (DA) release and decreases methamphetamine self-administration. Unfortunately, tolerance develops to the ability of lobelane to decrease these behavioral effects of methamphetamine. Lobelane has low water solubility, which is problematic for drug development. The aim of the current study was to determine the pharmacological effect of replacement of the N-methyl moiety with a chiral N-1,2-dihydroxypropyl (N-1,2-diol) moiety, which enhances water solubility, altering the configuration of the N-1,2-diol moiety and incorporating phenyl ring substituents into the analogs. To determine VMAT2 selectivity, structure-activity relationships also were generated for inhibition of DA and serotonin transporters. Analogs with the highest potency for inhibiting DA uptake at VMAT2 and at least 10-fold selectivity were evaluated further for ability to inhibit methamphetamine-evoked DA release from superfused striatal slices. (R)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-793A), the (R)-4-methoxyphenyl-N-1,2-diol analog, and (R)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol (GZ-794A), the (R)-1-naphthyl-N-1,2-diol analog, exhibited the highest potency (Ki ∼30 nM) inhibiting VMAT2, and both analogs inhibited methamphetamine-evoked endogenous DA release (IC50 = 10.6 and 0.4 μM, respectively). Thus, the pharmacophore for VMAT2 inhibition accommodates the N-1,2-diol moiety, which improves drug-likeness and enhances the potential for the development of these clinical candidates as treatments for methamphetamine abuse.

Footnotes

  • This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA13519, DA016176].

  • The University of Kentucky holds patents on lobeline and the analogs described in the current work, which have been licensed by Yaupon Therapeutics, Inc. A potential royalty stream to D.B.H., G.Z., P.A.C., and L.P.D. may occur consistent with University of Kentucky policy. Both P.A.C. and L.P.D. are founders of, and have financial interest in, Yaupon Therapeutics, Inc.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    doi:10.1124/jpet.111.184770.

  • ABBREVIATIONS:

    DAT
    dopamine transporter
    5-HT
    5-hydroxytryptamine (serotonin)
    ANOVA
    analysis of variance
    DA
    dopamine
    DTBZ
    dihydrotetrabenazine
    EC
    electrochemical detection
    GBR 12909
    1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
    GZ-252C
    para-methoxyphenyl lobelane
    GZ-745A
    (R)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol
    GZ-745B
    (S)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol
    GZ-790A
    (R)-3-[2,6-cis-di(3-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-790B
    (S)-3-[2,6-cis-di(3-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-791A
    (R)-3-[2,6-cis-di(3-fluorophenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-791B
    (S)-3-[2,6-cis-di(3-fluorophenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-792A
    (R)-3-[2,6-cis-di(2-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-792B
    (S)-3-[2,6-cis-di(2-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-793A
    (R)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-793B
    (S)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-794A
    (R)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol
    GZ-794B
    (S)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol
    GZ-795A
    (R)-3-[2,6-cis-di(2,4-dichlorophenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-795B
    (S)-3-[2,6-cis-di(2,4-dichlorophenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-796A
    (R)-3-[2,6-cis-di(4-biphenylethyl)piperidin-1-yl]propane-1,2-diol
    GZ-796B
    (S)-3-[2,6-cis-di(4-biphenylethyl)piperidin-1-yl]propane-1,2-diol
    GZ-797A
    (R)-3-[2,6-cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol
    GZ-797B
    (S)-3-[2,6-cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol
    HPLC
    high-performance liquid chromatography
    N-1,2-diol
    N-1,2-dihydroxypropyl
    Ro-4-1284
    (2R,3S,11bS)-2-ethyl-3-isobutyl-9,10-dimethoxy-2,2,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol
    SAR
    structure-activity relationship
    SERT
    serotonin transporter
    UKCP-110
    cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride
    UKMH-106
    (3Z,5Z)-3,5-bis(2,4-dichlorobenzylidene)-1-methylpiperidine
    VMAT2
    vesicular monoamine transporter 2.

  • Received June 3, 2011.
  • Accepted July 20, 2011.
  • Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 339 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 339, Issue 1
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Pharmacology of Lobelane-Diol Analogs

David B. Horton, Kiran B. Siripurapu, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics October 1, 2011, 339 (1) 286-297; DOI: https://doi.org/10.1124/jpet.111.184770

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleDrug Discovery and Translational Medicine

Pharmacology of Lobelane-Diol Analogs

David B. Horton, Kiran B. Siripurapu, Guangrong Zheng, Peter A. Crooks and Linda P. Dwoskin
Journal of Pharmacology and Experimental Therapeutics October 1, 2011, 339 (1) 286-297; DOI: https://doi.org/10.1124/jpet.111.184770
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • C. Butyricum Alleviates bone loss after Bariatric Surgery
  • Running title: Antimuscarinic effect of mirabegron
  • Cx43 Activity and Modulation in the Myometrium
Show more Drug Discovery and Translational Medicine

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics